VRCA: Advancing late-stage dermatology assets with strong clinical data and global expansion underway
Significant progress was highlighted in commercializing YCANTH for molluscum and advancing phase III trials for common warts and basal cell carcinoma. Strategic partnerships, robust clinical data, and global expansion efforts position the company for key data readouts and market growth in the next…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.